Abstract
A newly-constructed antibody-like molecule containing the gp120-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes. Its long plasma half-life, other antibody-like properties, and potential to block all HIV isolates, make it a good candidate for therapeutic use.
MeSH Terms
Acquired Immunodeficiency Syndrome/immunology,metabolism,therapy
Adjuvants, Immunologic/chemical synthesis,metabolism,pharmacokinetics
Animals
Antigens, Surface/administration & dosage,chemical synthesis,immunology
Binding Sites, Antibody
Binding, Competitive
Cell Adhesion Molecules
Cell Line
Drug Design
HIV Envelope Protein gp120
Half-Life
Humans
Immunoglobulin G/administration & dosage,metabolism
Mice
Rabbits
Receptors, Complement/analysis
Receptors, Fc/analysis
Receptors, HIV
Receptors, Virus/administration & dosage,immunology
Retroviridae Proteins/metabolism
Chemicals
Adjuvants, Immunologic
Antigens, Surface
Cell Adhesion Molecules
HIV Envelope Protein gp120
Immunoglobulin G
Receptors, Complement
Receptors, Fc
Receptors, HIV
Receptors, Virus
Retroviridae Proteins
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Capon D J
Department of Molecular Biology, Genentech, Inc., South San Francisco, California 94080.
Chamow S M
Mordenti J
Marsters S A
Gregory T
Mitsuya H
Byrn R A
Lucas C
Wurm F M
Groopman J E